Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H36O7 |
Molecular Weight | 484.5812 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=C(OC)C(=CC=C1OCCCOC2=CC=C3CCC(OC3=C2CCC)C(O)=O)C(C)=O
InChI
InChIKey=ZVVCSBSDFGYRCB-UHFFFAOYSA-N
InChI=1S/C28H36O7/c1-5-8-21-23(13-10-19-11-14-25(28(30)31)35-26(19)21)33-16-7-17-34-24-15-12-20(18(3)29)27(32-4)22(24)9-6-2/h10,12-13,15,25H,5-9,11,14,16-17H2,1-4H3,(H,30,31)
SC-41930 has been shown to be a specific LTB4 receptor antagonist both in vitro and in vivo. SC-41930 can produce significant anti-inflammatory effects. The anti-inflammatory activity of SC-41930 could be attributed to postreceptor inhibition of inflammatory mediator production by human neutrophil and other cells in addition to antagonism of human neutrophil LTB4 receptors.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
In vivo characterization of zymosan-induced mouse peritoneal inflammation. | 1994 Jun |
|
Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor. | 1994 Sep |
|
Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. | 1995 May 26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1658813
Curator's Comment: mice data
1 mg/kg pretriatment (-30 min) before 6-trans-LTB4 injection
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2561214
SC-41930 was evaluated for effects on human neutrophil chemotaxis and degranulation. At concentrations up to 100 uM, SC-41930 alone exhibited no effect on neutrophil migration, but dose-dependently inhibited neutrophil chemotaxis induced by leukotriene B4 (LTB4) in a modified Boyden chamber. Concentrations of SC-41930 from 0.3 uM to 3 uM competitively inhibited LTB4-induced chemotaxis with a pA2 value of 6.35.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
164102
Created by
admin on Fri Dec 15 15:52:12 GMT 2023 , Edited by admin on Fri Dec 15 15:52:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EVH7O0422T
Created by
admin on Fri Dec 15 15:52:12 GMT 2023 , Edited by admin on Fri Dec 15 15:52:12 GMT 2023
|
PRIMARY | |||
|
114999
Created by
admin on Fri Dec 15 15:52:12 GMT 2023 , Edited by admin on Fri Dec 15 15:52:12 GMT 2023
|
PRIMARY | |||
|
120072-59-5
Created by
admin on Fri Dec 15 15:52:12 GMT 2023 , Edited by admin on Fri Dec 15 15:52:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY